A Comprehensive Review on Drug Profile of Benralizumab

This comprehensive review explain that the drug profile of benralizumab, a monoclonal antibody approved by the FDA for the management of severe eosinophilic asthma and other eosinophilic conditions. Highlighting asthma as a chronic inflammatory disorder characterized by eosinophilic excess, the review classifies treatment options including corticosteroids, leukotriene modifiers, biologics, and bronchodilators. Specifically focusing on benralizumab, the review details its mechanism of action as an IL-5 receptor antagonist, leading to eosinophil depletion via apoptosis and antibody-dependent cell-mediated cytotoxicity. The pharmacokinetic properties reveal a dose-proportional profile with a half-life of 15.5 days and prevalent routes of administration by subcutaneous injection. Compared to mepolizumab, benralizumab demonstrates superior efficacy in reducing exacerbations and improving lung function, particularly in patients with elevated eosinophil counts. Despite its therapeutic advantages, potential adverse effects such as hypersensitivity reactions necessitate careful patient monitoring. This review emphasizes the significance of benralizumab as a targeted therapy in eosinophilic asthma, advocating for its role in clinical practice while recognizing the importance of ongoing assessment for optimal patient outcomes.